melatonin has been researched along with Atherogenesis in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the effects of melatonin on the serum asymmetric dimethylarginine (ADMA) levels and the expressions of vaspin, visfatin, dimethylarginine dimethylaminohydrolase (DDAH), and signal transducer and activator of transcription-3 (STAT-3) for evaluation of endothelial function and inflammation in the hypercholesterolemic rats." | 8.31 | The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats. ( Aslan, G; İlhan, N; Sahin, K; Sahna, E; Sezgin, D; Tuzcu, M, 2023) |
| "Treatment with melatonin reduced/prevented functional and morphological changes induced by chronic ischemia on penile structure and function." | 7.83 | Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia. ( Andersson, KE; Mitsui, T; Nomiya, M; Sawada, N; Takeda, M; Zarifpour, M, 2016) |
| "Melatonin (MLT) is an endogenous indole compound with numerous biological activities that has been associated with atherosclerosis (AS)." | 7.81 | Melatonin alleviates myosin light chain kinase expression and activity via the mitogen-activated protein kinase pathway during atherosclerosis in rabbits. ( Cheng, X; Wan, Y; Wang, Y; Xu, Y; Zhou, Q; Zhu, H, 2015) |
| "Atherosclerosis is currently concerned as a chronic inflammatory process, which is response to an endothelial damage." | 6.44 | [Melatonin in the treatment of atherosclerosis]. ( Broncel, M; Chojnowska-Jezierska, J; Koziróg-Kołacińska, M, 2007) |
| "The aim of this study was to investigate the effects of melatonin on the serum asymmetric dimethylarginine (ADMA) levels and the expressions of vaspin, visfatin, dimethylarginine dimethylaminohydrolase (DDAH), and signal transducer and activator of transcription-3 (STAT-3) for evaluation of endothelial function and inflammation in the hypercholesterolemic rats." | 4.31 | The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats. ( Aslan, G; İlhan, N; Sahin, K; Sahna, E; Sezgin, D; Tuzcu, M, 2023) |
| " Melatonin and its nuclear receptor retinoid-related orphan receptor alpha (RORα) have been reported to have some protective effects on the development of atherosclerosis." | 3.96 | Melatonin prevents endothelial dysfunction in SLE by activating the nuclear receptor retinoic acid-related orphan receptor-α. ( Chen, D; Du, F; Huang, H; Li, J; Liu, X; Lu, L; Lu, Y; Zhang, C, 2020) |
| " Elevated plasma homocysteine is a risk factor for atherosclerosis and Alzheimer's disease, and the marked decline in adenosyl methionine with aging leads to dysregulation of methionine metabolism and hyperhomocysteinemia." | 3.88 | ( McCully, KS, 2018) |
| "Treatment with melatonin reduced/prevented functional and morphological changes induced by chronic ischemia on penile structure and function." | 3.83 | Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia. ( Andersson, KE; Mitsui, T; Nomiya, M; Sawada, N; Takeda, M; Zarifpour, M, 2016) |
| "Melatonin (MLT) is an endogenous indole compound with numerous biological activities that has been associated with atherosclerosis (AS)." | 3.81 | Melatonin alleviates myosin light chain kinase expression and activity via the mitogen-activated protein kinase pathway during atherosclerosis in rabbits. ( Cheng, X; Wan, Y; Wang, Y; Xu, Y; Zhou, Q; Zhu, H, 2015) |
| "The secretion of melatonin, a pleiotropic hormone mainly synthesized by the pineal gland, typically decreases with age and may be associated with the development of aging-related pathologic conditions such as cardiovascular disease." | 3.80 | Urine 6-sulfatoxymelatonin levels are inversely associated with arterial stiffness in post-menopausal women. ( Lee, DC; Lee, JY, 2014) |
| "Melatonin may have a preventive effect on atherosclerosis by regulating sleep quality and circadian biological rhythmicity." | 3.80 | Association between urinary 6-sulfatoxymelatonin excretion and arterial stiffness in the general elderly population: the HEIJO-KYO cohort. ( Kurumatani, N; Obayashi, K; Saeki, K, 2014) |
| "This study evaluated the role of cyclophilin A (CyPA) in early phase of atherosclerosis and also examined the atheroprotective effects of melatonin due to its antioxidant properties." | 3.79 | Endothelial and vascular smooth muscle cell dysfunction mediated by cyclophylin A and the atheroprotective effects of melatonin. ( Favero, G; Rezzani, R; Rodella, LF; Stacchiotti, A, 2013) |
| "Several pathological conditions, including hypertension, atherosclerosis, diabetes, ischemia/reperfusion injury and nicotine-induced vasculopathy, are associated with vascular endothelial dysfunction characterized by altered secretory output of endothelial cells." | 3.79 | Vascular endothelial cells and dysfunctions: role of melatonin. ( Castrezzati, S; Favero, G; Foglio, E; Lonati, C; Rezzani, R; Rodella, LF; Rossini, C, 2013) |
| "Melatonin has atheroprotective effects by acting on different pathogenic signaling processes; these result from its direct free radical scavenger activity, its indirect antioxidant properties and its anti-inflammatory actions." | 2.50 | Melatonin and its atheroprotective effects: a review. ( Favero, G; Reiter, RJ; Rezzani, R; Rodella, LF, 2014) |
| "Atherosclerosis is currently concerned as a chronic inflammatory process, which is response to an endothelial damage." | 2.44 | [Melatonin in the treatment of atherosclerosis]. ( Broncel, M; Chojnowska-Jezierska, J; Koziróg-Kołacińska, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (9.68) | 29.6817 |
| 2010's | 17 (54.84) | 24.3611 |
| 2020's | 11 (35.48) | 2.80 |
| Authors | Studies |
|---|---|
| Ajoolabady, A | 1 |
| Bi, Y | 1 |
| McClements, DJ | 1 |
| Lip, GYH | 1 |
| Richardson, DR | 1 |
| Reiter, RJ | 5 |
| Klionsky, DJ | 1 |
| Ren, J | 2 |
| Sun, X | 1 |
| Chen, L | 3 |
| Gui, QJ | 1 |
| Wang, Z | 1 |
| Gao, Z | 1 |
| Zheng, Y | 1 |
| Kou, J | 1 |
| Song, D | 1 |
| Yu, X | 1 |
| Dong, B | 1 |
| Chen, T | 1 |
| Yang, Y | 1 |
| Gao, X | 1 |
| Wang, Q | 1 |
| Ye, T | 1 |
| Yang, W | 1 |
| Zhang, X | 2 |
| Li, H | 1 |
| Yang, L | 2 |
| Wang, X | 2 |
| Liu, C | 2 |
| Deng, P | 1 |
| Pan, L | 1 |
| Cheng, J | 1 |
| Yu, Z | 1 |
| Pi, H | 1 |
| Zhou, Z | 1 |
| Hu, H | 1 |
| Cong, L | 1 |
| Liu, X | 3 |
| Bai, Y | 2 |
| Qin, Q | 1 |
| Zhao, L | 1 |
| Shi, Y | 1 |
| Guo, Z | 1 |
| Hu, ZP | 2 |
| Fang, XL | 2 |
| Sheng, B | 1 |
| Guo, Y | 1 |
| Yu, YQ | 1 |
| Xie, M | 1 |
| Tang, Q | 1 |
| Nie, J | 1 |
| Zhang, C | 3 |
| Zhou, X | 2 |
| Yu, S | 1 |
| Sun, J | 1 |
| Cheng, X | 2 |
| Dong, N | 1 |
| Hu, Y | 1 |
| Huang, H | 1 |
| Chen, D | 1 |
| Lu, Y | 1 |
| Li, J | 2 |
| Du, F | 1 |
| Lu, L | 1 |
| Sezgin, D | 1 |
| Aslan, G | 1 |
| Sahin, K | 1 |
| Tuzcu, M | 1 |
| İlhan, N | 1 |
| Sahna, E | 1 |
| Zhao, Z | 1 |
| Zhang, R | 2 |
| Ma, B | 1 |
| Niu, S | 1 |
| Di, X | 1 |
| Ni, L | 1 |
| Chao, ML | 1 |
| Luo, S | 1 |
| Zhou, M | 1 |
| Wang, J | 1 |
| Kong, C | 1 |
| Chen, J | 2 |
| Lin, Z | 1 |
| Tang, X | 2 |
| Sun, S | 1 |
| Chen, H | 1 |
| Wang, H | 1 |
| Wang, D | 1 |
| Sun, JP | 1 |
| Han, Y | 1 |
| Xie, L | 1 |
| Ji, Y | 1 |
| Zhang, Y | 1 |
| Bai, X | 1 |
| Lin, Y | 1 |
| Li, Z | 1 |
| Fu, J | 1 |
| Li, M | 1 |
| Zhao, T | 1 |
| Yang, H | 1 |
| Xu, R | 1 |
| Ju, J | 1 |
| Cai, B | 1 |
| Xu, C | 1 |
| Yang, B | 1 |
| Hurley, MJ | 1 |
| Deacon, RMJ | 1 |
| Beyer, K | 1 |
| Ioannou, E | 1 |
| Ibáñez, A | 1 |
| Teeling, JL | 1 |
| Cogram, P | 1 |
| McCully, KS | 1 |
| Obayashi, K | 2 |
| Saeki, K | 2 |
| Ma, S | 1 |
| Feng, J | 1 |
| Fan, M | 1 |
| Han, D | 1 |
| Li, X | 1 |
| Li, C | 1 |
| Wang, Y | 3 |
| Cao, F | 1 |
| Li, HY | 1 |
| Leu, YL | 1 |
| Wu, YC | 1 |
| Wang, SH | 1 |
| Ding, S | 1 |
| Lin, N | 1 |
| Sheng, X | 1 |
| Zhao, Y | 1 |
| Su, Y | 1 |
| Xu, L | 1 |
| Tong, R | 1 |
| Yan, Y | 1 |
| Fu, Y | 1 |
| He, J | 1 |
| Gao, Y | 1 |
| Yuan, A | 1 |
| Ye, L | 1 |
| Pu, J | 1 |
| Fang, N | 1 |
| Wang, XB | 1 |
| Qian, HY | 1 |
| Cao, Z | 1 |
| Cheng, Y | 1 |
| Wang, BN | 1 |
| Favero, G | 4 |
| Rodella, LF | 4 |
| Rezzani, R | 4 |
| Lee, JY | 1 |
| Lee, DC | 1 |
| Kurumatani, N | 1 |
| Wan, Y | 1 |
| Xu, Y | 1 |
| Zhou, Q | 1 |
| Zhu, H | 1 |
| Sawada, N | 1 |
| Nomiya, M | 1 |
| Zarifpour, M | 1 |
| Mitsui, T | 1 |
| Takeda, M | 1 |
| Andersson, KE | 1 |
| Iriti, M | 1 |
| Faoro, F | 1 |
| Pizza, V | 1 |
| Agresta, A | 1 |
| D'Acunto, CW | 1 |
| Festa, M | 1 |
| Capasso, A | 1 |
| Rossini, C | 2 |
| Foglio, E | 2 |
| Bonomini, F | 1 |
| Stacchiotti, A | 1 |
| Castrezzati, S | 1 |
| Lonati, C | 1 |
| Tailleux, A | 1 |
| Gozzo, A | 1 |
| Torpier, G | 1 |
| Martin-Nizard, F | 1 |
| Bonnefont-Rousselot, D | 1 |
| Lemdani, M | 1 |
| Furman, C | 1 |
| Foricher, R | 1 |
| Chevé, G | 1 |
| Yous, S | 1 |
| Micard, F | 1 |
| Bordet, R | 1 |
| Gardes-Albert, M | 1 |
| Lesieur, D | 1 |
| Teissier, E | 1 |
| Fruchart, JC | 1 |
| Fiévet, C | 1 |
| Duriez, P | 1 |
| Broncel, M | 1 |
| Koziróg-Kołacińska, M | 1 |
| Chojnowska-Jezierska, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Intervention Effect Of Melatonin On The Risk Of Cardiovascular Events And Malignant Tumors In The Elderly: A Prospective, Randomized Parallel Controlled Study Based On Large Cohorts[NCT04631341] | 10,000 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | |||
| Melatonin and Essential Arterial Hypertension[NCT05257291] | Phase 2 | 23 participants (Actual) | Interventional | 2018-02-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for melatonin and Atherogenesis
| Article | Year |
|---|---|
Melatonin-based therapeutics for atherosclerotic lesions and beyond: Focusing on macrophage mitophagy.
Topics: Animals; Atherosclerosis; Drug Therapy, Combination; Humans; Inflammation; Macrophages; Melatonin; M | 2022 |
The long-lived Octodon degus as a rodent drug discovery model for Alzheimer's and other age-related diseases.
Topics: Alzheimer Disease; Animals; Atherosclerosis; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug | 2018 |
[Thermal and Lighting Housing Environments and Circadian Blood Pressure Variability: Findings from the HEIJO-KYO Cohort].
Topics: Aged; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Cohort Studies; Co | 2018 |
Melatonin and its atheroprotective effects: a review.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; Gene Expression Regulation; Humans | 2014 |
Bioactivity of grape chemicals for human health.
Topics: Aging; Alkaloids; Animals; Antioxidants; Atherosclerosis; Cardiotonic Agents; Chemoprevention; Flavo | 2009 |
Neuroinflammation and ageing: current theories and an overview of the data.
Topics: Aging; Alzheimer Disease; Apoptosis; Atherosclerosis; Biological Evolution; Brain; Cellular Senescen | 2011 |
[Melatonin in the treatment of atherosclerosis].
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; Free Radicals; Humans; Melatonin; | 2007 |
24 other studies available for melatonin and Atherogenesis
| Article | Year |
|---|---|
The Potential of Melatonin to Treat Atherosclerosis by Targeting Mitochondria.
Topics: Antioxidants; Atherosclerosis; Humans; Melatonin; Mitochondria; Oxidative Stress | 2023 |
Melatonin inhibits atherosclerosis progression via galectin-3 downregulation to enhance autophagy and inhibit inflammation.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Autophagy; Down-Regulation; Galectin 3; Inflammation; M | 2023 |
Melatonin ameliorates atherosclerosis by suppressing S100a9-mediated vascular inflammation.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Inflammation; Melatonin; Mice; NF-kappa B | 2023 |
Melatonin alleviates pyroptosis by regulating the SIRT3/FOXO3α/ROS axis and interacting with apoptosis in Atherosclerosis progression.
Topics: Animals; Apoptosis; Atherosclerosis; Caspases; Humans; Melatonin; Mice; Nicotine; Pyroptosis; Reacti | 2023 |
Melatonin inhibits macrophage infiltration and promotes plaque stabilization by upregulating anti-inflammatory HGF/c-Met system in the atherosclerotic rabbit: USPIO-enhanced MRI assessment.
Topics: Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Contrast Medi | 2020 |
BMAL1-Downregulation Aggravates
Topics: Animals; Anti-Bacterial Agents; Antioxidants; Apolipoproteins E; ARNTL Transcription Factors; Athero | 2020 |
Melatonin prevents endothelial dysfunction in SLE by activating the nuclear receptor retinoic acid-related orphan receptor-α.
Topics: Animals; Atherosclerosis; Cytokines; Endothelium; Human Umbilical Vein Endothelial Cells; Humans; In | 2020 |
The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Hypercholesterolemia; Hyperlipidemias; Inflammation; Melaton | 2023 |
Melatonin attenuates smoking-induced atherosclerosis by activating the Nrf2 pathway via NLRP3 inflammasomes in endothelial cells.
Topics: Animals; Aorta; Atherosclerosis; Cell Line; Disease Models, Animal; Endothelial Cells; Endothelium, | 2021 |
S-nitrosylation-mediated coupling of G-protein alpha-2 with CXCR5 induces Hippo/YAP-dependent diabetes-accelerated atherosclerosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Atherosclerosis; Cells, Cultured; Cysteine; Diabetes | 2021 |
Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Diet, High-Fat; Endothelial Cells; Gene Expressi | 2018 |
Topics: Atherosclerosis; Dementia; Homocysteine; Humans; Hyperhomocysteinemia; Melatonin; Mitochondria; Oxid | 2018 |
Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition.
Topics: Animals; Atherosclerosis; Disease Progression; Forkhead Box Protein O3; Free Radical Scavengers; Inf | 2018 |
Melatonin Inhibits in Vitro Smooth Muscle Cell Inflammation and Proliferation and Atherosclerosis in Apolipoprotein E-Deficient Mice.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Apolipoproteins E; Atherosclerosis; Becaplermin; Cell Prol | 2019 |
Melatonin stabilizes rupture-prone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor RORα-dependent manner.
Topics: Animals; Atherosclerosis; Humans; Macrophages; Male; Melatonin; Mice; Mice, Knockout, ApoE; Nuclear | 2019 |
Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF-κB system in high-fat-fed rabbits.
Topics: Animals; Atherosclerosis; Diet, High-Fat; Inflammation; Male; Melatonin; NF-kappa B; Rabbits; Toll-L | 2013 |
Urine 6-sulfatoxymelatonin levels are inversely associated with arterial stiffness in post-menopausal women.
Topics: Aging; Atherosclerosis; Female; Humans; Logistic Models; Melatonin; Middle Aged; Odds Ratio; Postmen | 2014 |
Association between urinary 6-sulfatoxymelatonin excretion and arterial stiffness in the general elderly population: the HEIJO-KYO cohort.
Topics: Aged; Aged, 80 and over; Aging; Ankle Brachial Index; Atherosclerosis; Biomarkers; Body Mass Index; | 2014 |
Melatonin alleviates myosin light chain kinase expression and activity via the mitogen-activated protein kinase pathway during atherosclerosis in rabbits.
Topics: Animals; Aorta; Atherosclerosis; Capillary Permeability; Disease Models, Animal; Extracellular Signa | 2015 |
Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia.
Topics: Animals; Antioxidants; Atherosclerosis; Cholesterol, Dietary; Chronic Disease; Disease Models, Anima | 2016 |
Aging and vascular dysfunction: beneficial melatonin effects.
Topics: Aging; Animals; Antioxidants; Atherosclerosis; Cells, Cultured; Disease Models, Animal; Endothelium, | 2013 |
Endothelial and vascular smooth muscle cell dysfunction mediated by cyclophylin A and the atheroprotective effects of melatonin.
Topics: Animals; Antioxidants; Apolipoproteins E; Atherosclerosis; Cell Adhesion; Cell Movement; Cyclophilin | 2013 |
Vascular endothelial cells and dysfunctions: role of melatonin.
Topics: Atherosclerosis; Diabetes Mellitus; Endothelial Cells; Humans; Hypertension; Melatonin; Nicotine; Re | 2013 |
Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.
Topics: Animals; Antioxidants; Aorta; Apolipoproteins B; Atherosclerosis; Benzamides; Cattle; Cell Survival; | 2005 |